Answers are grounded in this paper and cite their sources.
A BCR-ABL fusion product identifies chronic myeloid leukemia as a clonal myeloproliferative tumor. Tyrosine kinase inhibitors have become more widely used to treat chronic myeloid leukemia, although there is still little known about their long-term negative effects, such as the possibility of additional cancers. The most common secondary malignancies reported in CML are localized to the gastrointestinal tract, prostate, lung, non- Hodgkins lymphoma, malignant melanoma and breast cancer. Herein,
No takes yet. Share an insight, caveat, or question.
Joseph et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: